Table 4.
HPV series initiation and series completion among children 11–17 years old, by sex
| Site | Males | Females | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Initiation | Completion | Initiation | Completion | |||||||
| % Vaccinated | % Vaccinated | |||||||||
| Total N |
Baseline (7/1/2013– 6/30/2014) |
Intervention (7/1/2014– 3/31/2015) |
Baseline (7/1/2013– 6/30/2014) |
Intervention (7/1/2014– 3/31/2015) |
Total N |
Baseline (7/1/2013– 6/30/2014) |
Intervention (7/1/2014– 3/31/2015) |
Baseline (7/1/2013– 6/30/2014) |
Intervention (7/1/2014– 3/31/2015) |
|
| Intervention sites | ||||||||||
| A | 639 | 50.5 | 60.0 | 25.6 | 39.1 | 624 | 63.3 | 71.4 | 36.2 | 49.1 |
| C | 189 | 68.7 | 78.3 | 28.0 | 44.9 | 201 | 73.1 | 79.1 | 42.7 | 56.2 |
| D | 890 | 39.3 | 50.1 | 20.3 | 33.9 | 925 | 53.8 | 65.1 | 38.7 | 50.4 |
| E | 53 | 58.4 | 75.4 | 20.7 | 28.3 | 80 | 71.2 | 83.7 | 40.0 | 51.2 |
| F | 473 | 41.2 | 52.2 | 24.3 | 38.9 | 514 | 45.7 | 56.2 | 33.2 | 43.1 |
| G | 71 | 52.1 | 70.4 | 22.5 | 46.4 | 65 | 70.7 | 76.9 | 53.8 | 61.5 |
| H | 48 | 72.9 | 79.1 | 31.2 | 52.0 | 51 | 64.7 | 78.4 | 43.1 | 50.9% |
| I | 29 | 48.2 | 55.1 | 41.3 | 48.2 | 37 | 62.1 | 64.8 | 35.1 | 48.6 |
| J | 27 | 88.8 | 100.0 | 66.6 | 74.0 | 26 | 96.1 | 100.0 | 73.0 | 84.6 |
| Intervention total | 2419 | 47.0* | 57.7** | 24.1* | 38.3** | 2523 | 57.8* | 67.5** | 38.1* | 49.7** |
| Percentage point difference between baseline and intervention periods | 10.7 | 14.2† | 9.7 | 11.6† | ||||||
| Control sites | ||||||||||
| L | 812 | 51.9 | 59.6 | 29.0 | 41.7 | 785 | 65.4 | 71.5 | 46.4 | 56.6 |
| M | 363 | 48.7 | 57.8 | 23.4 | 35.5 | 341 | 56.3 | 62.1 | 31.6 | 42.5 |
| N | 464 | 77.3 | 86.2 | 35.5 | 55.6 | 469 | 86.3 | 91.6 | 45.4 | 65.4 |
| O | 68 | 67.6 | 80.8 | 35.2 | 48.5 | 75 | 82.6 | 89.3 | 65.3 | 77.3 |
| P | 33 | 48.4 | 63.6 | 33.3 | 48.4 | 53 | 66.0 | 69.8 | 54.7 | 60.3 |
| Q | 79 | 27.8 | 36.7 | 12.6 | 18.9 | 81 | 53.0 | 59.2 | 32.0 | 37.0 |
| R | 57 | 22.8 | 42.1 | 8.7% | 19.2 | 60 | 61.6 | 66.6 | 35.0 | 46.6 |
| S | 57 | 35.0 | 40.3 | 15.7 | 26.3 | 46 | 50.0 | 54.3 | 32.6 | 32.6 |
| T | 473 | 58.3 | 69.5 | 28.7 | 43.7 | 440 | 67.9 | 75.6 | 45.6 | 59.7 |
| U | 465 | 56.5 | 61.9 | 40.4 | 50.9 | 456 | 63.5 | 68.8 | 52.1 | 60.5 |
| V | 113 | 49.5 | 60.1 | 16.8 | 30.0 | 129 | 69.7 | 72.0 | 46.5 | 53.4 |
|
| ||||||||||
| Control total | 2984 | 55.9* | 64.7** | 29.7* | 43.3** | 2935 | 67.8* | 73.6** | 45.1* | 56.8** |
| Percentage point difference between baseline and intervention periods | 8.8‡ | 13.6§ | 5.8‡ | 11.7§ | ||||||
Note: HPV vaccination rates are cumulative as of the end of each period.
P<0.001 for difference between males and females at baseline for series initiation and series completion, by Chi square test.
P<0.001 for difference between males and females at end of intervention for series initiation and series completion, by Chi square test.
No difference in percentage point increases between males and females in the intervention group for series initiation, by Chi square test.
P<0.01 for percentage point increases between males and females in the intervention group for series completion, by Chi square test.
P<0.001 for percentage point increases between males and females in the control group for series initiation, by Chi square test.
P<0.05 for percentage point increases between males and females in the control group for series completion, by Chi square test.